Loading…
Mewburn Ellis LLP
Active litigationThe forward-looking IP firm
About
Mewburn Ellis LLP is a European intellectual property firm whose About Us page states that founder John Clayton Mewburn "founded his intellectual property office in London in 1867" and that the firm is "now over 360 strong", with "55 partners and over 110 qualified patent and trade mark attorneys, solicitors and IP litigators spread across five offices in Europe". Its stated services span patents, trade marks and brands, designs, commercial IP and transactions, and contentious proceedings including post-grant proceedings, oppositions and appeals, IP litigation and the Unified Patent Court. Life sciences is a core practice, and the firm states its "IP specialists in the team defended patents for half of the top ten selling biologic drugs in 2020, with annual sales for these drugs amounting to over $40 billion."
Strategic positioning
Biotech-forward European prosecution and FTO, from early platforms to commercial portfolios.
Deterministic scores · rules-based, not AI iHow these scores are obtained: each one is computed from this profile's listed attributes — capability checkboxes, certifications, capacity figures and coverage — by a fixed formula, recomputed on every page load. Deterministic and rules-based means the score comes from a fixed, transparent formula over listed attributes — the same inputs always produce the same score. It is not AI: there is no model, no learning, and no hidden weighting. Whether a score is relevant to you depends on your specific project: a capability that raises the number may not matter for your work, and a niche strength your project needs may barely move it. Capability scores are a directional starting point, not a verdict. A lower score does not disqualify a company or consultant, and no decision should rest on the score alone — always contact the company directly to confirm the specifics for your project.
Manufacturing-IP focus iAdds 25 points if the firm declares a manufacturing-IP focus, plus 9 points per manufacturing technology area listed (sterile injectables, biologics, radiopharmaceuticals, biosimilars, drug-device combinations, mRNA/LNP), capped at 45, plus 8 points per manufacturing-IP service (CMC patents, trade secret governance, FTO opinions, patent term extension), capped at 30. Levels: 75+ Manufacturing-IP specialist | 50-74 Manufacturing-active | 25-49 Selective | below 25 Therapeutics-IP focused. Whether this dimension matters for you depends on your specific project.
17Therapeutics-IP focused
Life-sciences IP iAdds 4 points per technology area, capped at 30, plus 5 points per practice area, capped at 25, plus 4 points per jurisdiction, capped at 20, plus up to 25 points for technical depth based on the share of attorneys holding PhDs or advanced degrees. Levels: 80+ Premier life-sciences IP | 60-79 Strong | 40-59 Established | below 40 Emerging. Whether this dimension matters for you depends on your specific project.
65Strong
Technology areas
Cell & gene therapyBiologicsCRISPR / gene editingAntibody-drug conjugatesVaccinesDiagnostics
Practice areas
Patent prosecutionEPO oppositionFreedom-to-operate (FTO)IP due diligencePatent portfolio strategy
Jurisdictions
EPOUKIPOWIPO / PCTGermany (DPMA)
ME
Mewburn Ellis LLP
IP & patent counsel · United Kingdom
Live record · illustrative seed data · scores deterministic, rules-based — not AI.